The global Intrathecal Pumps Market is estimated at around USD 231.5 million in 2022. With a projected CAGR of 5.2% for the next ten years, the market is likely to reach a valuation of nearly USD 383.5 million by the end of 2032. Intrathecal pumps require substantially less medication compared to oral drugs, owing to which its demand is on a constant rise.
| Report Attributes | Details |
|---|---|
| Intrathecal Pumps Market Size (2021A) | USD 221.1 million |
| Estimated Market Value (2022E) | USD 231.5 million |
| Forecasted Market Value (2032F) | USD 383.5 million |
| Global Market Growth Rate (2022 to 2032) | 5.2% CAGR |
| United States Market (2022) | USD 79.4 million |
| Key Companies Covered | Medtronic; Smith’s Medical; Flowonix Medical Inc.; tricumed Medizintechnik GmbH; Teleflex Incorporated; Johnson and Johnson Services, Inc.; Durect Corporation; Medallion Therapeutics, Inc. |
Future Market Insights’ analysis reveals that in 2022 revenue through the Intrathecal Pumps Market is estimated at USD 231.5 million. Patients who have not seen relief from conservative pain management (CPT) treatments can benefit most from the adoption of intrathecal pumps. The intrathecal pumps market is one of the fastest-growing areas in pain management therapies around the globe.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global market for the Intrathecal Pumps Market expanded at a CAGR of 4.2% from 2017 to 2021. The National Cancer Institute estimates that 442.4 new instances of cancer are diagnosed annually for every 100 thousand men and women.
Since intrathecal pumps work directly in the CSF and enable pharmaceuticals to be absorbed more quickly and directly than oral treatments, they are more advantageous than oral medications. This has accelerated the global market for intrathecal pumps.
The United States will continue to be the largest consumer of the Intrathecal Pumps, throughout the analysis period accounting for over USD 51.7 million absolute dollar opportunity in the coming 10-year period.
Pain is a prevalent and clinically significant illness in the aging population. However, the use of intrathecal pumps has led to better results in the treatment of senior patients with pain. Unfortunately, evaluating pain in geriatric patients is problematic, mostly due to the complexity of multiple comorbidities. The demand for intrathecal pumps will continue to rise as the number of the elderly population grows. The WHO projects that by 2050, there will be 2 billion individuals worldwide who are 60 years of age or older.
The capacity of a pump to deliver medications where they are most frequently required, as well as their increased potency, reduced systemic exposure, and the amount necessary to have the desired pharmacologic effect, is anticipated to drive market expansion. For instance, Flowonix Medicals produced a 40 mL pump for injecting medications into the intrathecal region. The delivery device uses a pressure-driven, valve-gated delivery mechanism and has a battery life of more than 10 years, which can help prevent the need for future surgical procedures.
In comparison to the conservative pain management procedure for our initial implantation cycle, IDD therapy is less expensive. The following costs are cumulative USD 17,317 greater than those for the conservative pain management procedure in the month of IDD implantation, although IDD breaks even financially shortly after the second year post-implant. According to the lifetime analysis, IDD saves USD 3,111 per patient annually compared to conservative pain management.
The desire for affordable treatments like intrathecal pumps has increased in response to growing global concern over how to reduce rising healthcare costs. A patient satisfaction survey on intrathecal pumps conducted in 2020 found that 76.9% of respondents had avoided the hospital after receiving an intrathecal implant, which significantly reduced the expenditures associated with healthcare consumption.
Principal Consultant
The use of all intrathecal pumps has not yet been approved by the American Food and Drug Administration. The FDA has warned medical professionals and patients about the harmful repercussions of using medications that have not received FDA approval. Drugs that are approved for intrathecal use must also adhere to more stringent safety standards.
The market expansion could be hampered by hazards such as dosing errors, infections, pump failure, opioid withdrawal, and other conditions like muscular spasms, cognitive problems, discomfort, fever, vomiting, weakness, and heart or respiratory distress. CSF leak, surgical site infection, and catheter site irritation are examples of surgical complications. Between 0.5% and 2.0% of intrathecal implants result in surgical infections.
Additionally, it is projected that the global lack of anesthesiologists and neurosurgeons will have a negative effect on market growth. Intrathecal pumps are superior to conventional drug delivery methods in a number of ways, but their application is constrained by related technical and surgical issues. The technological issues include pump failure and catheter kinks, disconnections, and obstructions (battery depletion, pump inversion, & pump erosion). Although none of these mechanical faults provide a life-threatening risk, they all need specialized modification.
North America dominated the global intrathecal pumps market and accounted for a revenue share of over 40% in 2020. Growth in the market is anticipated to be fueled by the rising frequency of cancer and other related disorders, such as persistent back and neck pain. For instance, the Centers for Disease Control and Prevention (CDC) estimates that around 50 million Americans suffer from chronic pain.
Additionally, improving patient outcomes and safety is of the utmost significance. Several programs have been formed to do this in the United States. Another element influencing its expansion is the fact that North America spends significantly more on healthcare than any other region.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The United States will account for over 18.8 million of the global Intrathecal Pumps Market by the year 2032. The market growth from 2017 to 2021 was estimated at 3.5% CAGR. A malignant tumor of the brain or spinal cord affected over 24 thousand people in the United States in 2021, according to a report by the American Cancer Society.
The International Agency for Research on Cancer (IARC of WHO) recently released a report stating that there are now significantly more cancer patients. According to estimates, there are approximately 14.1 million cancer patients. Also, it was calculated that 8.2 million people will die from cancer each year. Future market growth is anticipated due to the rising incidence of cancer.
The market for intrathecal pumps in the United Kingdom. stood at USD 10.7 million in 2021. By 2032, the market in the country is projected to reach a valuation of USD 19.7 million, growing at a CAGR of 5.7% from 2022 to 2032. The market is expected to witness an absolute dollar opportunity of USD 8.4 million during the forecast period.
In Japan, the market for intrathecal pumps accounted for USD 9.4 million in 2021. From 2022 to 2032, the market accounted for an absolute dollar opportunity of USD 9 million, growing at a CAGR of 6.8%. The market in the country is expected to reach a valuation of USD 18.8 million by 2032.
The intrathecal pumps market in South Korea accounted for a valuation of USD 4.8 million in 2021. By 2032, the market is expected to reach a valuation of USD 8.3 million. Growing at a CAGR of 5.2%, the market is projected to garner an absolute dollar opportunity of USD 3.3 million.
The market for morphine intrathecal pumps is projected to grow at a CAGR of 4.8% from 2021 to 2032. One of the most efficient treatments for severe chronic pain, intrathecal morphine injection is typically used as a part of a long-term therapy plan. Since morphine opioids are used 90% of the time in clinical settings, which is considered to be the gold standard for the management of postoperative pain, it is anticipated that this will drive segment growth.
The market through pain application held the largest revenue share of more than 70% in 2021. The segment is estimated to grow at a CAGR of 4.9% from 2021 to 2032. Many chronic diseases, including cancer, include pain as a component, and chronic pain is emerging as a distinct health issue with serious consequences for individuals.
Around 1.5 billion people worldwide suffer from chronic pain, and its incidence rises with age, according to the School of Public Health at Boston University. About 50 million people in the United States suffer from chronic pain, with 20 million of those suffering from high-impact chronic pain, according to the Centers for Disease Control and Prevention (CDC).
Some of the key companies operating in the Intrathecal Pumps Market include Medtronic, Smiths Medical, Flowonix Medical Inc., triumphed Medizintechnik GmbH, Teleflex Incorporated, Johnson and Johnson Services, Inc., Durect Corporation, Medallion Therapeutics, Inc., Abbott, Baxter International Inc., Codman & Shurtleff, Inc., DePay Synthes, Summit Medical Group, B Braun Melsungen AG, Becton, Dickinson & Company and Fresenius Medical Care AG & Co. KGaA., and Zimmer Biomet.
Some of the recent developments by key providers of the Intrathecal Pumps Market are as follows:
Similarly, recent developments related to companies manufacturing Intrathecal Pumps have been tracked by the team at Future Market Insights, which is available in the full report.
The global market was valued at USD 221.1 million in 2021.
The market is set to witness a growth rate of 5.2% over the forecast period and be valued at USD 383.5 million by 2032.
The market expanded by 4.2% from 2017 through 2021.
The key players are Tricumed Medizintechnik GmbH, Arthrex Inc., Teleflex Incorporated, Flowonix Medical Inc, and Zimmer Biomet.
United States, United Kingdom, China, Japan, and South Korea are expected to drive the most sales growth in the Intrathecal Pumps Market.
The market in China accounts for USD 43.6 million by 2032.
The United States holds the largest market share of the global market with USD 51.7 million of absolute dollar opportunity.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032 5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Type 5.1. Baclofen 5.2. Bupivacaine 5.3. Clonidine 5.4. Morphine 5.5. Ziconotide 5.6. Other Types 6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Application 6.1. Spasticity 6.2. Pain 7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region 7.1. North America 7.2. Latin America 7.3. Europe 7.4. Asia Pacific 7.5. Middle East and Africa (MEA) 8. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 9. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 10. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 11. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 12. MEA Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 13. Key Countries Market Analysis 14. Market Structure Analysis 15. Competition Analysis 15.1. Tricumed Medizintechnik GmbH 15.2. Arthrex Inc. 15.3. Teleflex Incorporated 15.4. Flowonix Medical Inc. 15.5. Zimmer Biomet 15.6. Medtronic 15.7. Smith’s Medical 15.8. Durex Corporation
Explore Healthcare Insights
View Reports
Intrathecal Pumps Market
